Clinical-stage biopharmaceutical development - pain and addiction therapeutics
Strategic Profile
JanOne's mission is to bring treatments to the market for diseases that cause severe pain and to find non-addictive answers for treating pain. Its lead product candidate is JAN101, a patented oral and sustained release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities in patients with diabetes or peripheral artery disease to treat pain.
Cyborg Score Rationale
Early-stage biotech company with modest market cap (~$27M) and volatile stock performance. Clinical-stage pipeline with lead candidate JAN101; however, limited revenue generation and significant shareholder losses over three years temper near-term prospects.
Top Insights
Clinical-stage biotech focused on non-opioid pain management solutions addressing major public health crisis
Lead candidate JAN101 targets PAD (peripheral artery disease), a 8.5M+ patient population
Micro-cap company with market cap of approximately $27.14M and higher-than-market volatility (beta ~2.16)
Company maintains legacy recycling and technology operations alongside biotech focus